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Mitochondrial complex I (CI) deficiency is the most prevalent defect in the respiratory chain
in paediatric mitochondrial disease. This heterogeneous group of diseases includes serious
or fatal neurological presentations such as Leigh syndrome and there are very limited
evidence-based treatment options available. Here we describe that cell membrane-permeable
prodrugs of the complex II substrate succinate increase ATP-linked mitochondrial respiration
in CI-deficient human blood cells, fibroblasts and heart fibres. Lactate accumulation in
platelets due to rotenone-induced CI inhibition is reversed and rotenone-induced increase in
lactate:pyruvate ratio in white blood cells is alleviated. Metabolomic analyses demonstrate
delivery and metabolism of [13C]succinate. In Leigh syndrome patient fibroblasts, with a
recessive NDUFS2 mutation, respiration and spare respiratory capacity are increased by
prodrug administration. We conclude that prodrug-delivered succinate bypasses CI and
supports electron transport, membrane potential and ATP production. This strategy offers a
potential future therapy for metabolic decompensation due to mitochondrial CI dysfunction.
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P
aediatric mitochondrial disease due to complex I (CI)
deficiency is a heterogeneous group of disorders, and can be
due to alterations in either the nuclear or mitochondrial
genome. It is the most prevalent defect in the respiratory chain in
paediatric patients and often leads to serious or fatal neurological
presentations, such as Leigh syndrome1. There are currently very
limited evidence-based treatment options directed towards
mitochondrial respiratory chain dysfunction2,3. Succinate is a
mitochondrial substrate metabolized through complex II (CII).
It is not cell membrane-permeable and exogenously given
succinate has limited uptake into cells.
Here we describe that cell membrane-permeable prodrugs of
succinate provide increased ATP-linked mitochondrial oxygen
consumption in CI-deficient human cells and tissues, which offers
a potential future intervention for patients with metabolic
decompensation due to mitochondrial CI dysfunction.
Results
Drug development and screening. In a drug discovery program,
450 different prodrugs of succinate4 were designed, synthesized
and evaluated for cell permeability and ability to support
respiration independent of CI in human peripheral blood cells
from healthy donors (platelets and mononuclear cells (PBMCs))
using an Oroboros O2k respirometer. Three compounds were
selected for further evaluation: NV101-118 (NV118, diacetoxy-
methyl succinate), NV101-189 (NV189, bis-(1-acetoxy-ethyl)
succinate) and NV101-241 (NV241, 1-acetoxyethyl acetoxy-
methyl succinate) (Fig. 1a). This article focuses on NV189, but
qualitatively the results for all three prodrugs were similar and data
on the other compounds are presented as Supplementary Figs.
Increased CII-linked respiration. At 100mM, NV189 increased
mitochondrial oxygen consumption in intact platelets with CI
inhibition induced by the mitochondrial toxin rotenone (2 mM).
Neither succinate nor monomethyl succinate, a monoester of
succinate previously reported to be cell permeable5, increased
mitochondrial respiration (Fig. 1b; Supplementary Fig. 1a).
In cells with normal CI function, oxygen consumption was
also increased upon addition of 100mM NV189 (Fig. 1c;
Supplementary Fig. 1b). To exclude the possibility that
increased respiration was due to an induction of proton leak
through the mitochondrial inner membrane (uncoupling), the
platelets were treated with the ATP synthase inhibitor
oligomycin. This prompted a significant decrease in oxygen
consumption, which indicates the extent of respiration linked to
ADP phosphorylation (Fig. 1c; Supplementary Fig. 1b). Increased
substrate supply, rather than uncoupling, was further
demonstrated by measuring mitochondrial inner membrane
potential with the positively charged membrane-permeable
probe tetramethylrhodamine methyl ester (TMRM) in non-
quench mode using fluorescence-activated cell sorting. TMRM
fluorescence was increased in CI-inhibited human platelets
upon addition of 250 mM NV189 and fluorescence increased
further with ATP synthase inhibition, indicating mitochondrial
membrane hyperpolarization (Fig. 1d). Cells with maximal
uncoupled respiratory chain activity via titration of the
protonophore carbonyl cyanide p-(trifluoromethoxy) phenyl-
hydrazone (FCCP) increased oxygen consumption even more
with addition of 250 mM NV189, further indicating increased
substrate supply to the respiratory chain (Fig. 1e; Supplementary
Fig. 1c). In blood cells, pre-permeabilized with the detergent
digitonin, 250mM NV189 did not induce any increase in
respiration, while succinate control did, showing the need for
intracellular metabolism for succinate to be released and made
available to the mitochondria (Fig. 1f; Supplementary Fig. 1d).
To confirm that the increase in respiration is specifically due
to respiration through CII, a cell-permeable prodrug of the
CII inhibitor malonate, NV01-161, (NV161, diacetoxymethyl
malonate, Fig. 1h) was designed, synthesized and evaluated
(Supplementary Fig. 2). Intact cells exposed to succinate prodrugs
were treated with NV161 with ensuing decrease in respiration
(Fig. 1g; Supplementary Fig. 1e). The applicability of the platelet
data to other cell types was evaluated by assessing respiration in
PBMCs treated with NV189 with or without CI inhibition with
similar results to those in platelets (Fig. 1i,j; Supplementary
Fig. 1f,g).
Paediatric mitochondrial diseases primarily display symptoms
from energy intense organs such as the liver, brain, muscles,
retina and cochlea. In some reports, 30–40% of paediatric patients
with respiratory chain CI dysfunction present with cardio-
myopathy6,7, a condition that is linked to higher mortality8.
Human atrial heart muscle biopsies from elective surgery were
acquired and the fibres gently separated using forceps. The fibres
were incubated with the CI inhibitor rotenone and subsequently
treated with succinate prodrug, eliciting an increase in oxygen
consumption (Fig. 1k; Supplementary Fig. 1h).
Attenuated lactate production. A hallmark of mitochondrial
disease is lactic acidosis. When the mitochondrial energy pro-
duction fails to comply with demand, pyruvate is converted to
lactate to maintain the NADþ pool, causing increased lactate
levels and decreased pH in blood and cerebrospinal fluid in the
patients. About 80% of patients with mitochondrial disease
show signs of lactate accumulation6,8,9. We incubated human
platelets with or without 2 mM rotenone and measured lactate
accumulation in media over time. With CI inhibition, the cells
displayed a significantly higher lactate production than control,
4.30±0.24 mmol lactate per 109 cells per hour compared
with control level 1.73±0.5 (regression slope±s.d.), but with
incubation with NV189 the rotenone-induced lactate production
was similar to control level (1.26±0.19). To verify the viability of
the cell preparation, the glycolytic pathway upon drug addition
and the specificity of CII-mediated ATP supply, cells were
incubated with NV189, rotenone and an inhibitor of the
downstream respiratory chain complex III (antimycin A,
1 mgml 1), eliciting lactate production at the level of that of
rotenone alone (4.44±0.19; Fig. 1m,n; Supplementary Fig. 1i).
Metabolomics confirms metabolism of delivered succinate. To
elucidate the intracellular metabolism of NV189, a metabolomic
assay was performed on PBMCs from four healthy donors. Cells
were incubated with or without rotenone and with or without
NV189 for 20min. Using quantitative capillary electrophoresis
mass spectrometry (CE-MS), the concentrations of 116 metabolites
were determined. Delivery of intracellular succinate and ana-
plerosis of tricarboxylic acid (TCA) cycle intermediates were
confirmed (Fig. 2a; Supplementary Fig. 3). The lactate:pyruvate
ratio was increased when cells were inhibited with rotenone and
normalized when the cells were treated with NV189 (Fig. 1l).
No conclusive alterations due to drug treatment in metabolism of
succinyl-CoA-related amino acids or glycolysis could be shown.
Levels of cysteine were decreased, which could indicate oxidative
stress. To investigate the time course of intracellular metabolism of
delivered succinate, [1, 2, 3, 4-13C4]NV118 was synthesized,
whereby the carbon atoms in NV118 that upon release would
comprise the four carbon atoms in succinate were enriched with
the stable isotope 13C. This distinguishes between endogenous
TCA cycle intermediates and metabolites originating from the
prodrug-delivered succinate. NV118 rather than NV189 was used
due to relatively less complex synthesis. Human platelets were then
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incubated with [1, 2, 3, 4-13C4]NV118 for 7.5, 15, 30, 120 and
240min. Even at the first time point, [13C4]malate and
[13C4]citrate were observed, demonstrating rapid entry of
[13C4]succinate into the TCA cycle (Fig. 2b). There was also
[13C6]citrate present, which indicates that [13C]oxaloacetate or
[13C]malate had converted to pyruvate and through acetyl-CoA
formed citrate with [13C4]oxaloacetate (Fig. 2b; Supplementary
Fig. 4), demonstrating continuous metabolism in the TCA cycle.
The ratio of labelled species gradually declined with time but still
after 240min, there was a supply of labelled succinate available.
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Respiration increased in Leigh syndrome patient fibroblasts.
To evaluate the effect of NV189 on patient cells, fibroblasts from
a patient with Leigh syndrome due to recessive nuclear DNA
mutations in the structural CI gene NDUFS2 and three control
cell lines were investigated using a Seahorse Bioscience XFe 96
Extracellular Flux Analyzer (Fig. 3; Supplementary Fig. 5). The
patient fibroblasts have previously been shown to exhibit severely
decreased activity of CI, decreased CI assembly and lower
expression of CI structural proteins10. Pooled data from all
experiments (Fig. 3c,d; Supplementary Fig. 5c,d) revealed a 25%
decrease in basal oxygen consumption rate (OCR) and a 42%
reduction in maximum uncoupled respiration in the Leigh
syndrome patient cells compared with the mean of the control
cell lines. After addition of NV189, the OCR was similar between
Control
Rotenone
Rotenone + NV189
[13C] number
Glutamine 
Glutamate 
Phosphoenolpyruvic acid
Acetyl-CoA
0
20
40
60
80
100
7.5 15 30
min 
120 240
2-OG 
0
20
40
60
80
100
7.5 15 30
min 
120 240
cis-Aconitic acid
0
20
40
60
80
100
7.5 15 30
min 
120 240
6
5
4
3
2
1
0
Citric acid
Fumaric acid
0
20
40
60
80
100
7.5 15 30
min 
120 240
0
20
40
60
80
100
7.5 15 30
min 
120 240
0
20
40
60
80
100
7.5 15 30 
min 
120 240
Isocitric acid
0
20
40
60
80
100
7.5 15 30
min 
120240
Lactic acid
0
20
40
60
80
100
7.5 15 30
min 
120 240
Malic acid
0
20
40
60
80
100
7.5 15 30
min 
120 240
Succinic acid 
Pyruvic acid 
%
%
%
% %
%
%
%
Aspartate 
0
20
40
60
80
100
7.5 15 30
min 
120 240
% %
Oxaloacetic acid
Citric acid
cis-Aconitic acid
Isocitric acid
Succinic acid 
Fumaric acid
Malic acid
2-OG
a b
Oxaloacetic acid
0
0.0
1.0
2.0
0
2,500
5,000
0
500
1,000
25
50
75
0
100
150
0
100
200
50
pm
ol
 1
06
 
ce
lls
–
1
pm
ol
 1
06
 
ce
lls
–
1
pm
ol
 1
06
 
ce
lls
–
1
pm
ol
 1
06
 
ce
lls
–
1
pm
ol
 1
06
 
ce
lls
–
1
pm
ol
 1
06
 
ce
lls
–
1
Figure 2 | Intracellular metabolism of exogenous prodrug-delivered succinate. (a) TCA cycle intermediates in peripheral blood mononuclear
cells after 20min incubation with or without rotenone and NV189 quantified using capillary electrophoresis mass spectrometry, n¼4. Data presented
as mean and s.d. (b) Fraction of [13C] isotope labelled carbons in TCA cycle intermediates and related metabolites in human platelets incubated with
[1, 2, 3, 4-13C4]NV118 for 7.5, 15, 30, 120 or 240min. Mean of n¼ 2. 2-OG, 2-oxoglutaric acid.
Figure 1 | Effects of mitochondrial complex II stimulation by the succinate prodrug NV189. (a) Structures of NV118, NV189 and NV241, succinate
highlighted in red. (b) Respiration in platelets (plts) with rotenone-induced mitochondrial complex I (CI) inhibition. (c) ATP-generating respiration in
platelets. (d) Mitochondrial membrane potential in complex I-inhibited platelets, ratio of basal TMRM fluorescence, n¼4. (e) Respiration in platelets with
FCCP-induced uncoupling. (f) Respiration in digitonin-permeabilized platelets. (g) Effect on respiration in platelets with addition of the cell-permeable
complex II inhibitor NV161, * indicate significant difference between NV161 and vehicle, n¼4. (h) Structure of NV161, malonate highlighted in red.
(i) Respiration in peripheral blood mononuclear cells (PBMCs) with rotenone-induced CI inhibition, n¼4. (j) Convergent respiration in PBMCs, n¼4,
* indicate significant difference between pre and post dosing. (k) Respiration in human heart muscle fibres (HHMFs), n¼ 5. (l) Lactate:pyruvate ratio in
PBMCs at baseline, after rotenone CI inhibition and after treatment with NV189, n¼4. * indicates significant difference using Friedmans non-parametric
paired test with Dunn’s multiple comparisons test of all groups against control. For three data points, pyruvate was below detection limit and the estimated
lower-quantification limit was used for calculating the ratio. (m) Lactate accumulation in 2ml buffer containing 400 106 platelets, incubated with or
without rotenone, antimycin A and NV189, n¼ 5. (n) Lactate production in platelets, data quantification from previous panel. Mean with 95% confidence
interval. All respirometric experiments in human platelets were performed with n¼6 individuals donors if not otherwise stated. All data presented as mean
and s.e. if not otherwise stated. In all experiments, blood cells from separate donors are used for each n. *Po0.05, **Po0.01, ***Po0.001 (two-tailed
paired or unpaired Student’s t-test as appropriate, difference between test compound and control if not otherwise stated).
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patient and controls (Fig. 3d; Supplementary Fig. 5d). The patient
cells had lower maximum respiration compared with control
cells, but in the presence of NV189 the OCR of patient cells was
similar to that of untreated control cells (Fig. 3e and
Supplementary Fig. 5e). After rotenone inhibition of CI, both
cell types elicited clear remaining respiratory activity in cells
treated with NV189 (Fig. 3f; Supplementary Fig. 5f). The relative
contribution of flux through CII to maximum uncoupled
respiration for NV189 was 4.8% in the control cell lines and
3.8% in the Leigh syndrome cells. With treatment, this increased
to 15.9% in control cells and to 28.8% in patient cell (Fig. 3g,h;
Supplementary Fig. 5g,h), illustrating the dependence of CII
substrates in the patient cells to reach normal respiratory
function. When patient cells were treated with the prodrugs,
the spare respiratory capacity (respiratory reserve, the ability of
the cells to increase respiration from the endogenous baseline) as
percentage of the endogenous baseline was similar to that of the
control cell lines (Fig. 3i; Supplementary Fig. 5i). Succinate or
dimethyl succinate (an ester previously suggested to be cell
permeable11,12) did not exert any effects on either cell type
(Supplementary Fig. 6).
Discussion
Mitochondrial disorders frequently present early in life with
failure to thrive, myopathy and neuropathy, but the symptoms
are very diverse13. At least 1 in 8,000 births will develop a
mitochondrial disease14. Mitochondrial diseases are usually
progressive and have a fluctuating clinical course. Periods of
deterioration, such as during an intercurrent viral infection,
are prompted by the increase in metabolic demand that the
mitochondria cannot compensate for, resulting in metabolic
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Figure 3 | Succinate prodrug treatment of mitochondrial complex I-deficient Leigh syndrome patient fibroblasts. (a,b) Oxygen consumption rate (OCR)
in three control fibroblast cell lines and a mitochondrial complex I-deficient cell line (recessive NDUFS2 mutation) treated with NV189 or vehicle.
(c–f) Quantification of OCR in control and patient fibroblasts for each respiratory state. (g,h) Relative contribution of complex I- and complex II-linked
respiration to maximum uncoupled respiration in patient cells and control cell lines. (i) Spare respiratory capacity, defined as per cent increase from
endogenous baseline to maximum uncoupled respiration. Data presented as mean and s.e. of n¼ 3 experiments from separate cell culture flasks performed
with eight technical replicates each time for each cell lines. Data from the three control cell lines are pooled. *Po0.05 (two-tailed unpaired Student’s t-test,
difference between Leigh and control cell lines).
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decompensation15. It is an area of large unmet medical need as
few evidence-based treatment options are available2. We describe
here three model compounds of the first generation of a new
pharmacological strategy to metabolically support these patients
during time of metabolic decompensation. The current
compounds lack sufficient plasma stability to be suitable for
in vivo use. A cell-permeable prodrug of succinate can enter the
cell independent of active uptake and subsequently release
succinate. By supplying the mitochondria with substrates for
CII, cells that are unable to comply with metabolic demand due to
limitations at CI, or upstream thereof, may increase ATP
production through oxidative phosphorylation, demonstrated
here by the normalization of spare respiratory capacity in
metabolically defect patient cells (Fig. 3i). By supporting aerobic
metabolism, the relative dependence on glycolysis for ATP
generation is alleviated and lactate production is attenuated
(Figs 1n and 4). Utilizing a cell-permeable prodrug strategy to
deliver a TCA cycle intermediate to the intracellular space is a
feasible pharmacologic strategy with potential benefit in
conditions affecting mitochondrial function, such as CI
dysfunction or TCA cycle intermediate depletion in organic
acidemias. Here we demonstrate that prodrug-delivered succinate
can alleviate metabolic decompensation due to CI-related
mitochondrial dysfunction.
Methods
Human peripheral blood cells. The blood cell protocols were approved by the
regional ethics committee of Lund University, Sweden (permit no. 2013/181), and
written informed consent was acquired from each participant. From healthy
volunteers, venous blood was drawn to K2EDTA tubes (Vacutainer, BD, Franklin
Lakes, USA) via venous puncture. Platelets were isolated with consecutive
centrifugation steps as previously described16. Peripheral blood mononuclear cells
(PBMCs) were isolated using Lymphoprep (Axis-Shield, Dundee, Scotland).
Erythrocytes and PBMCs were loosely pelleted by 10min centrifugation at 500g.
The pellet was resuspended in saline, layered on a Ficoll gradient and
centrifuged at 800g for 20–30min. The resulting leukocyte layer was collected,
resuspended in saline and pelleted by 5min centrifugation at 250g. The supernatant
was removed and the pellet resuspended in 100–200 ml of saline. Blood cells were
counted using an automated hematocytometer (SweLab Alfa, Boule Diagnostics,
Sweden). The number of biological replicates (blood cells derived from different
individual donors) are provided in the respective figure legends for all experiments.
Human cardiac muscle samples. Biopsies of human cardiac muscle were
obtained at the Department of Cardiothoracic Surgery, Skåne University Hospital,
Lund, Sweden. Pre-surgery informed consent was obtained from patients under-
going planned open-heart surgery such as mitral valve repair or maze procedure
for treatment of atrial fibrillation. Only superfluous tissue that otherwise would
have been discarded or located behind the suture line for the cannulation catheter
was collected (up to 2 g was collected, 50–100mg used for each experiment).
Ethical permission was granted by the regional ethical review board of Lund,
Sweden (permit no. 2013/271, 2013/701). The biopsy was immediately transferred
to ice-cold preservation solution (BIOPS; 10mM Ca-EGTA buffer, 0.1 mM free
calcium, 20mM imidazole, 20mM taurine, 50mM K-MES, 0.5mM dithiothreitol,
6.56mM MgCl2, 5.77mM ATP and 15mM phosphocreatine, pH 7.1). It was
thereafter dissected under microscope using forceps to gently separate the fibres
and remove any fat and connective tissue. Biopsy wet weight was obtained before
respiratory measurements (Precisa 40SM-200A, Abbot, USA).
Cultured fibroblasts. Permit for research on fibroblasts was granted by the
Newcastle and North Tyneside 1 NRES Committee (REC reference 2002/205).
A cultured skin fibroblast cell line from a patient with clinical Leigh syndrome due
to a deficiency in the nuclear encoded structural mitochondrial CI protein NDUFS2
(p.Arg118Gln; p.Met292Thr mutations), and relevant control cell lines from
healthy donors were provided by the Wellcome Trust Centre for Mitochondrial
Research at Newcastle University, UK10. The fibroblasts were cultured in minimum
essential medium (MEM) supplemented with 10% fetal bovine serum, 1% MEM
vitamins, 1% MEM non-essential amino acids, 2mM L-glutamine, 50 mgml 1
streptomycin, 50Uml 1 penicillin, 50mgml 1 uridine and 1mM sodium
pyruvate at 37 C and 5% CO2. Cells were collected using trypsin and split or used
for analysis atB70–80% confluence and counted using an automated cell counter
(TC20, Bio-Rad, Hercules, USA).
Respirometry. For cells in monolayers, the Seahorse Bioscience XFe 96
Extracellular Flux Analyser (Seahorse Bioscience, North Billerica, USA) was the
instrument of choice, and for cells in suspension such as blood cells the Oroboros
O2k (Oroboros Instruments, Innsbruck, Austria) was used. Respiratory measure-
ments using Oroboros O2k were performed in stirred (750 r.p.m.) 2ml glass
chambers at 37 C. The media MiR05 (sucrose 110mM, HEPES 20mM, taurine
20mM, K-lactobionate 60mM, MgCl2 3mM, KH2PO4 10mM, EGTA 0.5mM and
bovine serum albumin 1 g l 1, pH 7.1) was used in all experiments16,17. Data were
recorded using the DatLab software version 4, 5 or 6 (Oroboros Instruments).
Correction for instrumental background and air calibration was performed
according to the manufacturer’s instructions.
All experiments with platelets were performed with cell concentrations of
200 106 cells per ml and all experiments with PBMCs with 5 106 cells per ml.
In experiments with human heart fibres, B10mg of tissue was used in each run.
To inhibit mitochondrial CI, rotenone (2 mM) was used and to inhibit
mitochondrial complex III, antimycin A (1mgml 1) was used. ATP synthase was
inhibited using oligomycin (1mgml 1), evaluating the contribution of respiration
independent of ADP phosphorylation. Maximum uncoupled respiration of the
electron transport system was induced by titration of the protonophore carbonyl
cyanide FCCP until no further increase in respiration was detected. The test
compound or control substances (succinate, dimethyl succinate, monomethyl
succinate, malonate, dimethyl malonate or dimethylsulphoxide (DMSO)) were
dosed as indicated in each figure.
Cell membrane
Cytoplasm
Outer 
membrane
Intermembrane
space
Inner 
membrane
Matrix
CI CII
CIII
CIV
CV
Low
Normal
Increased
SuccinateNADH
TCA cycle Pyruvate
Lactate
Glycolysis
ATP
H+
H+
Q
C
e–e–
e–
e–
e–
H+
ADP
Low
Normal
Increased
Cell membrane
Cytoplasm
Outer
membrane
Intermembrane
space
Inner
membrane
Matrix
CI CII
CIII
CIV
CV
Succinate
Succinate
SuccinateNADH
TCA cycle Pyruvate
Lactate
Glycolysis
ATP
H+
H+
Q
C
e–
e–
e–
e–
e–
ADP
a CI-deficiency
b Succinate prodrug delivery
H+H+
H+
Figure 4 | Delivery of succinate to the intracellular space via a prodrug
strategy. (a) Dysfunction in mitochondrial complex I reduces electron flow
through the respiratory chain, shift metabolism towards glycolysis, induce
lactate accumulation and limit ATP production. (b) Cell membrane-
permeable prodrugs of succinate access the intracellular space and release
succinate, enabling increased electron transport, respiration and ATP
production through complex II, thus bypassing the deficiency in
mitochondrial complex I.
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Respirometric measurements in fibroblasts were performed using a Seahorse
Bioscience XFe 96 Extracellular Flux Analyzer. The day before the experiment,
fibroblasts were seeded out at 25,000 cells per well in cell growth medium in
collagen-coated 96-well plates and kept at 37 C and 5% CO2 overnight. Before the
experiment, the growth medium was replaced by XF-Base Medium containing
2mM L-glutamine, 5mM sodium pyruvate and 10mM glucose (pH 7.4) and the
cells were kept at 37 C 1 h at atmospheric O2 and CO2. Oxygen consumption was
measured at routine state and after addition of 500mM of NV241 or NV189, its
vehicle DMSO, dimethyl succinate or disodium succinate, followed by different
concentrations of FCCP (0.125, 0.5, 1.0 and 1.5 mM), 2 mM rotenone and 1 mgml 1
antimycin A. After FCCP and drug addition, the first data point was generally used,
if not another data point was clearly higher, and for the remaining states the last
data point before the subsequent addition was used. The FCCP dosing resulting in
the highest uncoupled respiration was chosen for analysis for each experiment with
each cell line and treatment.
All respirometric measurements, with the exception of the human heart fibre
data, were corrected for non-mitochondrial oxygen consumption, obtained after
the addition of antimycin A.
Lactate. Platelets (n¼ 5 individual donors, 200 106 cells per ml) were incubated
in PBS for 4 h with rotenone (2 mM), rotenone and antimycin A (1mgml 1)
combined or the vehicle for rotenone (DMSO). At t¼ 60min, additions of 250 mM
NV118, NV189, NV241 or vehicle (DMSO) were initiated and repeated every
30min throughout the experiment. Lactate levels were determined every 30min
using a Lactate ProTM 2 blood lactate meter (Arkray, Alere AB, Lidingo¨,
Sweden)18. Incubation was performed at 37 C at a stirrer speed of 750 r.p.m.
Mitochondrial membrane potential. Mitochondrial membrane potential in
isolated human platelets (200 106ml 1) was measured using a flow cytometer
FACSAria III (BD, Franklin Lakes, USA) with Diva version 7.0 acquisition
and analysis software, using the probe TMRM (Life Techologies, Ref: T668),
in non-quench mode (30 nM)19 excited by 561 nM 40mW laser and collected on
582/15 band pass filter. CD41a-APC (BD Pharmingen, Clone HIP8, Ref: 559777) at
18 times dilution was used to assess platelet activation. Samples were incubated
with the probes in MiR05 for 30min at room temperature. CI was inhibited using
2 mM rotenone. NV189 (250 mM) or DMSO control was added to the samples,
followed by oligomycin (1 mgml 1), FCCP (20 mM) and antimycin A (1mgml 1),
the two latter additions as internal controls. Data software used was FlowJo 10
(Tree Star, Ashland, USA). Statistical analyses were performed, and all figures were
generated using Prism 6 (GraphPad Software).
Metabolomics. Isolated human PBMCs (16–25 106ml 1) were incubated at
37 C in 2ml MiR05 with 5mM glucose and with rotenone 2mM or DMSO control.
NV189 (250mM; 0.5mM total) or DMSO control was added in two subsequent
additions. Samples were centrifuged at 4,600g for 4min and the supernatant dis-
carded in two cycles with resuspension of pellet in 1.5ml of 5% mannitol solution
before the second run. To each sample, 800ml of methanol and 550ml of solution of
the internal standard (H3304-1002, Human Metabolome Technologies Inc., Tsur-
uoka, Japan) were added and 1ml of the extracted solution was taken for cen-
trifugation at 2,300g at 4 C for 5min. Thereafter, 400ml of the supernatant was
filtered at 9,100g at 4 C until no liquid remained. The extract was dried in a
centrifugal evaporator (1,500 r.p.m., 1,000Pa) and put in  80 C until analysis.
Samples were analysed using capillary electrophoresis time-of-flight mass spectro-
metry (CE-TOFMS) for cationic compounds and capillary electrophoresis tandem
mass spectrometry (CE-MS/MS) for anionic compounds (Agilent Technologies,
Santa Clara, USA), as previously described20. Peaks detected in CE-TOFMS analysis
were extracted using automatic integration software (MasterHands ver.2.16.0.15
developed at Keio University) and those in CE-MS/MS analysis were extracted using
automatic integration software (MassHunter Quantitative Analysis B.06.00, Agilent
Technologies) to obtain peak information including m/z, migration time and peak
area. The peak area was then converted to relative peak area. The peaks were
annotated based on the migration times in CE and m/z values determined by
TOFMS. Putative metabolites were then assigned from Human Metabolome
Technologies (HMT) metabolite database on the basis of m/z and migration time.
All the metabolite concentrations were calculated by normalizing the peak area of
each metabolite with respect to the area of the internal standard and using standard
curves, which were obtained by three-point calibrations. The lactate:pyruvate ratio
was analysed using Friedman’s non-parametric paired test for comparison between
three groups or more with Dunn’s multiple comparisons test of all groups against
control. For three data points (one data point in the group treated with only
rotenone and two data points in the group treated with rotenone and NV189),
pyruvate was below the quantification limit. The estimated lower-quantification limit
for pyruvate was between 16.96 and 20.55pmol per 106 cells and a mean of these two
values was used for calculating the lactate:pyruvate ratio for the missing data points.
Experiments were performed by the service provider Human Metabolome
Technologies Inc. (Tsuruoka, Japan). Cells from the same four healthy volunteers
were used for each experimental group.
Isotope labelling. NV118 was synthesized incorporating all four carbons in the
central succinate structure of the molecule with [13C] isotopes. Isolated platelets
(800 106ml 1) were kept at 37 C in 2ml MiR05 containing 5mM glucose. [1, 2,
3, 4-13C4]NV118 was added in two boluses to a final concentration of 0.5mM and
the samples were incubated for 15, 30, 120 or 240min. Extracts were prepared as
described above. Metabolome measurements were carried out through Human
Metabolome Technology Inc., Tsuruoka, Japan. Target metabolites and their
isotopomers were annotated based on their theoretical m/z value and migration
time21. Cells from the same two healthy volunteers were used for each experimental
group.
Statistics. Statistical analyses were performed, and all figures generated, using
Prism 6 (GraphPad Software, La Jolla, USA) if not otherwise stated. A P value of
o0.05 was considered statistically significant. No blinding or randomization was
performed, except for the metabolomics assays, where the lab performing the
analyses was blinded to the intervention allocated to the samples. Data from blood
cell respirometry have previously been reported to be normally distributed and
parametric tests were used16.
Data availability. All relevant data are contained within the paper and
Supplementary Information files or available from the authors upon request.
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